natgillin/translations-raw huggingface dataset:
The pharmacokinetics of darbepoetin alfa has been studied clinically in chronic renal failure patients following intravenous and subcutaneous administration. 
Farmakokinetiko darbepoetina alfa so raziskali pri bolnikih s kronično odpovedjo ledvic po intravenski in subkutani uporabi.
Blood and lymphatic system disorders 
Bolezni krvi in limfatičnega sistema neznana2
• Stomach area (abdomen), except for a 5 cm (2-inch) area right around your navel 
• področje želodca (trebuh), razen 5 cm okoli popka
In kidney failure, the kidney does not produce enough of the natural hormone erythropoietin which can often cause anaemia. 
Pri odpovedi ledvic v ledvicah ne nastaja dovolj naravnega hormona eritropoetina; pogosta posledica tega je anemija.
Appropriate dose titration between 500 mcg, 300 mcg, and 150 mcg should be considered. 
V poštev pride ustrezno titriranje odmerka med 500 µg, 300 µg in 150 µg.
If your doctor has decided to change your treatment from r-HuEPO (erythropoietin produced by gene-technology) to Aranesp, they will choose whether you should receive your Aranesp injection once weekly or once every two weeks. 
Če se zdravnik odloči, da vam namesto r-HuEPO (genskotehnološko pridobljenega eritropoetina) predpiše zdravilo Aranesp, bo tudi določil, ali morate injekcijo zdravila Aranesp dobiti enkrat na teden ali enkrat na dva tedna.
Convulsions were common in the placebo groups. 
V skupinah s placebom so bile konvulzije pogoste.
Insert the needle fully into the skin as shown by your doctor, nurse or pharmacist. 
Zabodite iglo do konca v kožo, kot so vam pokazali zdravnik, medicinska sestra ali farmacevt.
Do not try to warm the pre-filled pen by using a heat source such as hot water or microwave. 
Ne poskušajte ogrevati brizge z viri toplote kot sta vroča voda ali mikrovalovna pečica.
Per the Guideline on Summary of Product Characteristics (Revision 2, September 2009), frequency of ADRs identified in the post marketing setting was determined using the “Rule of three”. 
V skladu z dokumentom Guideline on Summary of Product Characteristics (revizija 2, september 2009) je bila pogostnost neželenih učinkov, prepoznanih v obdobju trženja zdravila, določena z uporabo “pravila trojke”.
Push the plunger with a slow constant pressure, always keeping your skin pinched, until the syringe is empty. 
Kožo ves čas držite ter s počasnim in stalnim pritiskom potiskajte bat, dokler brizge ne izpraznite.
Correction of anaemia in paediatric patients with once monthly Aranesp dosing frequency has not been studied. 
Odpravljanje anemije z uporabo zdravila Aranesp enkrat na mesec pri pediatrični populaciji ni raziskano.
In studies performed in rats and rabbits no clinically relevant evidence of harmful effects with respect to pregnancy, embryonal/ foetal development, parturition or postnatal development was observed. 
V študijah na podganah in kuncih niso opazili klinično pomembnih znakov škodljivih učinkov, kar zadeva brejost, razvoj zarodka/ploda, skotitev ali postnatalni razvoj.
In patients with a poor haemoglobin response to Aranesp, alternative explanations for the poor response should be considered (see sections 4.4 and 5.1). 
Pri bolnikih, ki imajo slab odziv hemoglobina na zdravilo Aranesp, je treba upoštevati druge možne vzroke za slab odziv (glejte poglavji 4.4 in 5.1).
Put the original package with any unused pre-filled syringes back in the refrigerator. 
Položite originalno pakiranje s še ne uporabljenimi napolnjenimi injekcijskimi brizgami nazaj v hladilnik.
Aranesp is administered either subcutaneously or intravenously as described in the posology. 
Zdravilo Aranesp se uporablja subkutano ali intravensko, kot je opisano v poglavju Odmerjanje.
In all cases, call your doctor or healthcare provider. 
V vsakem od teh primerov se posvetujte z zdravnikom ali zdravstvenim delavcem.
- Your doctor should try to keep your haemoglobin between 10 and 12 g/dL. 
- Zdravnik si mora prizadevati, da bi vam hemoglobin ohranil med 100 in 120 g/l.
Thereafter the haemoglobin can be measured at longer intervals. 
Potem lahko hemoglobin kontrolirate v daljših presledkih.
PHARMACEUTICAL FORM AND CONTENTS 1 single use pre-filled syringe. 
FARMACEVTSKA OBLIKA IN VSEBINA 1 napolnjena injekcijska brizga za enkratno uporabo.
Contents of the pack and other information Instructions for injecting with the Aranesp pre-filled syringe 
Vsebina pakiranja in dodatne informacije Navodila za injiciranje z napolnjeno injekcijsko brizgo Aranesp
Remove the needle and let go of your skin. 
Izvlecite iglo in kožo spustite.
Production of endogenous erythropoietin is impaired in patients with chronic renal failure and the primary cause of their anaemia is due to erythropoietin deficiency. 
Nastajanje endogenega eritropoetina je okvarjeno pri kronični odpovedi ledvic; primarni vzrok anemije pri takšnih bolnikih je pomanjkanje eritropoetina.
The pharmacokinetics of darbepoetin alfa in paediatric patients (2 to 16 years) with CRF who were either receiving or not receiving dialysis was assessed for sampling periods up to 2 weeks (336 hours) after one or two subcutaneous or intravenous doses. 
Farmakokinetiko darbepoetina alfa pri pediatričnih bolnikih (starih od 2 do 16 let) s kronično boleznijo ledvic, ki so bili ali niso bili na dializi, so preučili v obdobju vzorčenja do 2 tednov (336 ur) po enem ali dveh subkutanih ali intravenskih odmerkih.
• an observed 9% increase in risk for PD or death in the epoetin alfa plus SOC group from a primary analysis and a 15% increased risk that cannot be statistically ruled out in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 10 to 12 g/dL (6.2 to 7.5 mmol/L). 
• povzročila opaženo 9 % povečanje tveganja za napredovanje bolezni ali smrt v skupini z epoetinom alfa in standardno oskrbo iz primarne analize in 15 % povečanje tveganja, ki ga statistično ni mogoče izključiti, pri bolnicah z metastatskim rakom dojke, zdravljenih s kemoterapijo, kadar so prejemale odmerke za doseganje razpona koncentracije hemoglobina od 100 do 120 g/l (od 6,2 do 7,5 mmol/l).
With the grey cap off, place the pre-filled pen on your skin at 90 degrees. 
Sivi pokrovček mora biti odstranjen; prislonite napolnjeni injekcijski peresnik na kožo pod kotom 90 stopinj.
Do not recycle the pre-filled pen or sharps disposal container or throw them into household rubbish. 
Ne reciklirajte napolnjenega injekcijskega peresnika ali vsebnika za ostre odpadke ter ju ne vrzite med gospodinjske odpadke.
Window Medicine Make sure the medicine in the window is a clear and colourless liquid. 
Prepričajte se, da je zdravilo v okencu bistra in brezbarvna tekočina.
In the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls. 
V odprti študiji ni bilo razlike v celotnem preživetju bolnikov, zdravljenih z rekombinantnim humanim eritropoetinom, in bolnikov v kontrolni skupini.
Clinical studies have demonstrated that adult patients receiving r-HuEPO one, two or three times weekly may be converted to once weekly or once every other week Aranesp. 
Klinične študije so pokazale, da lahko odrasli bolniki, ki dobivajo r-HuEPO enkrat, dvakrat ali trikrat na teden, preidejo na zdravilo Aranesp enkrat na teden ali enkrat na dva tedna.
• Additional risk minimisation measures for Aranesp solution for injection in pre-filled pen 
• Dodatni ukrepi za zmanjševanje tveganj za zdravilo Aranesp v obliki raztopine za injiciranje v napolnjenem injekcijskem peresniku
H Firmly push the pre-filled pen down onto your skin until it stops moving. 
H Trdno pritisnite napolnjeni injekcijski peresnik ob kožo, dokler se ne neha premikati.
Clinical data in paediatric patients has demonstrated that patients receiving r-HuEPO two or three times weekly may be converted to once weekly Aranesp, and those receiving r-HuEPO once weekly may be converted to once every other week Aranesp. 
Klinični podatki pri pediatričnih bolnikih kažejo, da lahko tisti, ki dobivajo r-HuEPO dvakrat ali trikrat na teden, preidejo na zdravilo Aranesp enkrat na teden, tisti, ki dobivajo r-HuEPO enkrat na teden, pa na zdravilo Aranesp enkrat vsak drugi teden.
The syringes may be presented in either blistered (1- and 4-pack), with or without an automatic needle guard or non-blistered packaging (1-pack only). 
Brizge so lahko v pakiranju s pretisnimi omoti (pakiranje po 1 oz. 4) z avtomatičnim ščitnikom igle ali brez njega, ali v pakiranju brez pretisnih omotov (samo pakiranje po 1).
A Discard the used pre-filled syringe and other supplies in a sharps disposal container. 
A Zavrzite uporabljeno injekcijsko brizgo in drugo opremo v vsebnik za ostre odpadke.
How to use Aranesp 
Kako uporabljati zdravilo Aranesp
Aranesp should not affect your ability to drive or use machinery. 
Zdravilo Aranesp ne bi smelo vplivati na vašo sposobnost upravljanja vozil in strojev.
If you forget to use Aranesp 
Če ste pozabili uporabiti zdravilo Aranesp
In patients with solid tumours or lymphoproliferative malignancies, if the haemoglobin value exceeds 12 g/dL (7.5 mmol/L), the dosage adaptation described in section 4.2 should be closely respected, in order to minimise the potential risk of thromboembolic events. 
Če hemoglobin pri bolnikih s čvrstimi tumorji ali limfoproliferativnimi malignomi preseže 120 g/l (7,5 mmol/l), natančno upoštevajte prilagoditev odmerka, opisano v poglavju 4.2, da boste zmanjšali morebitno tveganje za trombembolične incidente.
Rotate the injection sites and inject slowly to avoid discomfort at the site of injection. 
Mesto injiciranja krožno menjajte, zdravilo pa injicirajte počasi, da se boste izognili neprijetnemu občutku na mestu injiciranja.
What Aranesp looks like and contents of the pack 
Izgled zdravila Aranesp in vsebina pakiranja
AUC(0-∞) was similar between adult and paediatric patients with CRF following subcutaneous administration. 
AUC(0-∞) po subkutani uporabi je bila pri odraslih in pediatričnih bolnikih s kronično boleznijo ledvic podobna.
In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see sections 4.2 and 5.1). 
Pri bolnikih, ki imajo slab odziv hemoglobina na epoetine, je treba upoštevati druge možne vzroke za slab odziv (glejte poglavji 4.2 in 5.1).
The syringes are provided either with (1- and 4-pack) or without (1-pack) a blister-wrapping. 
Brizge so opremljene v pretisnih omotih (pakiranje po 1 in 4) ali brez njih (pakiranje po 1).
If you stop using Aranesp 
Če ste prenehali uporabljati zdravilo Aranesp
The median (quartile 1, quartile 3) time to achieve haemoglobin correction (≥ 10.0 g/dL and ≥ 1.0 g/dL increase from baseline) was 5 weeks for both once every two week (3, 7 weeks) and once monthly dosing (3, 9 weeks). 
Mediani (1. kvartil, 3. kvartil) čas do dosežene odprave anemije (≥ 100 g/l in porast za ≥ 10 g/l od izhodišča) je bil 5 tednov tako med uporabo enkrat na dva tedna (3 tedne, 7 tednov) kot med uporabo enkrat na mesec (3 tedne, 9 tednov).
Aranesp is used to treat symptomatic anaemia that is associated with chronic renal failure (kidney failure) in adults and children. 
Zdravilo Aranesp uporabljamo za zdravljenje simptomatske anemije, ki spremlja kronično odpoved ledvic, pri odraslih in otrocih.
Following monthly administration of darbepoetin alfa, at subcutaneous doses ranging from 0.6 to 2.1 mcg/kg, the terminal half-life was 73 hours (SD 24). 
Po uporabi darbepoetina alfa enkrat na mesec v subkutanih odmerkih od 0,6 do 2,1 µg/kg je bil terminalni razpolovni čas 73 ur (standardni odklon 24).
Subcutaneous use is preferable in patients who are not receiving haemodialysis to avoid the puncture of peripheral veins. 
Pri bolnikih, ki niso na hemodializi, ima prednost subkutana uporaba, ker tako ni potrebno zbadanje perifernih ven.
Window turns yellow when the injection is done 
Ko je injiciranje končano, postane okence rumeno
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). 
Metaanaliza celotnih podatkov o preživetju je pokazala točkovno oceno razmerja ogroženosti 1,06 v korist kontrolnih oseb (95 % IZ: 1,00, 1,12; 53 preskušanj in 13.933 bolnikov); za bolnike z rakom, ki so dobivali kemoterapijo, je bilo razmerje ogroženosti za celotno preživetje 1,04 (95 % IZ: 0,97, 1,11; 38 preskušanj in 10.441 bolnikov).
It is important that you do not try to give yourself the injection unless you have received training from your doctor, nurse or pharmacist. 
Pomembno je, da si injekcij ne poskušate dajati sami, dokler vas tega ne nauči zdravnik, medicinska sestra ali farmacevt.
• Sharps disposal container 
• vsebnik za odlaganje ostrih odpadkov
In patients with cancer receiving chemotherapy the etiology of anaemia is multifactorial. 
Pri onkoloških bolnikih, ki dobivajo kemoterapijo, je v etiologijo anemije vpletenih več dejavnikov.
• Blood clots (thrombosis) 
• krvni strdki (tromboza)
Cancer patients receiving chemotherapy 
Onkološki bolniki, ki dobivajo kemoterapijo
In a prospective, randomised double-blind, placebo-controlled study conducted in 314 lung cancer patients receiving platinum containing chemotherapy there was a significant reduction in transfusion requirements (p < 0.001). 
V prospektivni, randomizirani, dvojno slepi, s placebom kontrolirani študiji pri 314 bolnikih z rakom na pljučih, ki so dobivali kemoterapijo s platino, so ugotovili značilno zmanjšanje potreb po transfuziji (p < 0,001).
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients 
Zdravljenje simptomatske anemije pri odraslih in pediatričnih bolnikih s kronično odpovedjo ledvic
The active substance of Aranesp is darbepoetin alfa produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1). 
Učinkovina v zdravilu Aranesp je darbepoetin alfa, pridobljen z gensko tehnologijo v ovarijskih celicah kitajskega hrčka (CHO-K1).
Important: Always keep the sharps disposal container out of the sight and reach of children. 
Pomembno: Vsebnik za ostre odpadke vedno shranjujte nedosegljivega otrokom.
Half-life was also similar between adult and paediatric patients with CRF following both intravenous and subcutaneous administration. 
Tudi razpolovni čas je bil pri odraslih in pediatričnih bolnikih s kronično boleznijo ledvic podoben, tako po intravenski kot po subkutani uporabi.
- The other ingredients are sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, polysorbate 80 and water for injections. 
- Druge sestavine zdravila so natrijev hidrogenfosfat, natrijev dihidrogenfosfat, natrijev klorid, polisorbat 80 in voda za injekcije.
Do not use the pre-filled pen if the medicine is cloudy or discoloured or contains flakes or particles. 
Ne uporabite napolnjenega injekcijskega peresnika, če je zdravilo motno ali obarvano ali vsebuje kosmiče ali delce.
If you have forgotten a dose of Aranesp, you should contact your doctor to discuss when you should inject the next dose. 
Če ste pozabili odmerek zdravila Aranesp, se pogovorite z zdravnikom, da vam bo povedal, kdaj si injicirajte naslednji odmerek.
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported (see section 4.4). 
Poročali so o hudih kožnih neželenih učinkih, vključno s Stevens-Johnsonovim sindromom (SJS) in toksično epidermalno nekrolizo (TEN), ki so lahko življenjsko nevarni ali smrtni (glejte poglavje 4.4).
The recommended initial dose is 500 mcg (6.75 mcg/kg) given once every three weeks, or once weekly dosing can be given at 2.25 mcg/kg body weight. 
Priporočeni začetni odmerek je 500 µg (6,75 µg/kg) enkrat na tri tedne, uporabiti pa je mogoče tudi odmerjanje 2,25 µg/kg telesne mase enkrat na teden.
• Blood clots in a dialysis access 
• krvni strdki v pristopu za dializo
In clinical studies, an increased risk of death, serious cardiovascular or cerebrovascular events including stroke, and vascular access thrombosis was observed when ESAs were administered to target a haemoglobin of greater than 12 g/dL (7.5 mmol/L). 
V kliničnih študijah so ugotovili večje tveganje smrti ter resnih kardiovaskularnih in cerebrovaskularnih dogodkov, vključno z možgansko kapjo in trombozo žilnega pristopa, če so ESA uporabljali tako, da je bil ciljni hemoglobin večji od 120 g/l (7,5 mmol/l).
Patients with CRF experienced greater risks for death and serious cardiovascular events when administered ESAs to target higher versus lower haemoglobin levels (13.5 g/dL (8.4 mmol/L) versus 11.3 g/dL (7.1 mmol/L); 14 g/dL (8.7 mmol/L) versus 10 g/dL (6.2 mmol/L) in two clinical studies. 
V dveh kliničnih študijah je bilo tveganje smrti in resnih srčno-žilnih dogodkov pri bolnikih s kronično odpovedjo ledvic večje, če je bil cilj zdravljenja z ESA višji hemoglobin, kot če je bil cilj nižji (135 g/l (8,4 mmol/l) v primerjavi z 113 g/l (7,1 mmol/l); 140 g/l (8,7 mmol/l) v primerjavi z 100 g/l (6,2 mmol/l)).
Patients with solid tumours (e.g., lung, breast, colon, ovarian cancers) and lymphoid malignancies 
Te klinične študije so vključile bolnike s čvrstimi tumorji (npr. rakom pljuč, dojke, kolona, jajčnika) in limfatičnimi malignomi (npr. limfomom, diseminiranim plazmocitomom).
The results showed non-inferiority for the primary endpoint of overall survival with a median survival for darbepoetin alfa versus placebo of 9.5 and 9.3 months, respectively (stratified HR 0.92; 95% CI: 0.831.01). 
Rezultati so pokazali neinferiornost pri celokupnem preživetju, ki je bilo primarni opazovani dogodek; mediano preživetje je bilo pri zdravljenju z darbepoetinom alfa v primerjavi s placebom 9,5 oziroma 9,3 meseca (stratificirano razmerje ogroženosti 0,92; 95 % IZ: 0,83; 1,01).
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.08 in favour of controls (95% CI: 0.99, 1.18; 42 trials and 8,167 patients). 
Ocena ogroženosti na podlagi metaanalize podatkov o celotnem preživetju je bila 1,08 v korist kontrolne skupine (95 % IZ: 0,99, 1,18; 42 preskušanj in 8.167 bolnikov).
The terminal half-life of darbepoetin alfa is 21 hours (SD 7.5) when administered intravenously. 
Terminalni razpolovni čas intravensko apliciranega darbepoetina alfa je 21 ur (standardni odklon 7,5).
• Fluid retention (oedema) 
• zastajanje tekočine (edemi)
• Avoid injecting into areas with scars or stretch marks. 
• Izognite se injiciranju v predele, kjer so brazgotine ali strije.
Platelet counts and haemoglobin level should also be monitored at regular intervals. 
V rednih presledkih je treba kontrolirati tudi število trombocitov in koncentracijo hemoglobina.
In isolated cases, neutralising anti-erythropoietin antibody mediated pure red cell aplasia (PRCA) associated with Aranesp therapy have been reported predominantly in patients with CRF treated subcutaneously. 
V posameznih primerih so v povezavi z zdravljenjem z zdravilom Aranesp poročali o čisti aplaziji rdečih celic (PRCA) zaradi nevtralizirajočih protieritropoetinskih protiteles, pretežno pri bolnikih s kronično odpovedjo ledvic, ki so zdravilo dobivali subkutano.
For all adults and paediatric patients ≥ 11 years of age not on dialysis, Aranesp could also be given as an injection once monthly. 
Vsem odraslim in pediatričnim bolnikom, starim ≥ 11 let, ki niso na dializi, je zdravilo Aranesp možno dati tudi kot injekcijo enkrat na mesec.
• Your healthcare provider has prescribed the Aranesp pre-filled pen for injection into the tissue just under the skin (subcutaneous use). 
• Zdravstveni delavec vam je predpisal zdravilo Aranesp v napolnjenem injekcijskem peresniku za injiciranje v tkivo tik pod kožo (subkutana uporaba).
During the evaluation period (weeks 29-33), the mean (95% CI) weekly equivalent dose was 0.20 (0.17, 0.24) mcg/kg in the once every two week arm and 0.27 (0.23, 0.32) mcg/kg in the once monthly arm. 
Med obdobjem ocenjevanja (29. do 33. teden) v tej študiji je bil povprečni (95 % IZ) tedenski ekvivalentni odmerek 0,20 (0,17, 0,24) μg/kg med prejemniki enkrat na dva tedna in 0,27 (0,23, 0,32) μg/kg med prejemniki enkrat na mesec.
Excipients: sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, polysorbate 80, water for injections. 
Pomožne snovi: natrijev hidrogenfosfat, natrijev dihidrogenfosfat, natrijev klorid, polisorbat 80, voda za injekcije.
Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients). 
Pri bolnikih s kronično odpovedjo ledvic so izvedli kumulativne post-hoc analize kliničnih študij ESA (bolniki na dializi, bolniki, ki niso na dializi, bolniki s sladkorno boleznijo in bolniki brez sladkorne bolezni).
Aranesp is a sterile but unpreserved product. 
Zdravilo Aranesp je sterilno, vendar ne vsebuje konzervansov.
The secondary endpoint of progression free survival was 4.8 and 4.3 months, respectively (stratified HR 0.95; 95% CI: 0.87-1.04), ruling out the pre-defined 15% risk increase. 
Preživetje brez napredovanja bolezni, ki je bilo sekundarni opazovani dogodek, je bilo 4,8 oziroma 4,3 meseca (stratificirano razmerje ogroženosti 0,95; 95 % IZ: 0,87; 1,04), s čimer so izključili predvideno 15 % povečanje tveganja.
It must be a clear, colourless or slightly pearly liquid. 
Tekočina mora biti bistra, brezbarvna ali rahlo bisernata.
At the time of clinical data cutoff, the median progression free survival (PFS) per investigator assessment of disease progression was 7.4 months in each arm (HR 1.09, 95% CI: 0.99, 1.20), indicating the study objective was not met. 
Ob zamejitvi kliničnih podatkov je bilo mediano preživetje brez napredovanja bolezni po raziskovalčevi oceni napredovanja bolezni 7,4 meseca v obeh skupinah (razmerje ogroženosti 1,09; 95 % IZ: 0,99; 1,20), kar kaže, da cilj študije ni bil dosežen.
Convulsions have been reported in patients receiving darbepoetin alfa (see section 4.4). 
Pri bolnikih, ki so dobivali darbepoetin alfa, so poročali o konvulzijah (glejte poglavje 4.4).
Alternatively, in patients not on dialysis, the following initial doses can also be administered subcutaneously as a single injection: 0.75 mcg/kg once every two weeks or 1.5 mcg/kg once monthly. 
Pri bolnikih, ki niso na dializi, je druga možnost subkutana uporaba sledečih začetnih odmerkov v eni injekciji: 0,75 µg/kg enkrat na dva tedna ali 1,5 µg/kg enkrat na mesec.
Non-response to therapy with Aranesp should prompt a search for causative factors. 
Če se bolnik na terapijo z zdravilom Aranesp ne odzove, je treba raziskati vzročne dejavnike za to.
• Keep the pre-filled pen and all medicines out of the reach of children. 
• Napolnjeni injekcijski peresnik in vsa zdravila shranjujte nedosegljivo otrokom!.
b Thromboembolic events adverse reactions includes PT embolism, thrombosis, deep vein thrombosis, jugular vein thrombosis, venous thrombosis, arterial thrombosis, pelvic venous thrombosis, peripheral embolism, pulmonary embolism, as well as thrombosis in device from SOC product issues. 
b Neželeni učinek trombembolični dogodki vključuje naslednje PT: embolija, tromboza, globoka venska tromboza, tromboza jugularne vene, venska tromboza, arterijska tromboza, tromboza medenične vene, periferna embolija, pljučna embolija ter tudi tromboza v pripomočku za organski sistem “težave povezane z zdravilom”.
The vial contains either 25, 40, 60, 100, 200 or 300 micrograms of darbepoetin alfa. 
Viala vsebuje 25, 40, 60, 100, 200 ali 300 mikrogramov darbepoetina alfa.
Aranesp is available in packs of 1 or 4 pre-filled syringes with automatic needle guard in a blister wrapping. 
Zdravilo Aranesp je na voljo v pakiranjih z 1 ali 4 napolnjenimi injekcijskimi brizgami z avtomatičnim ščitnikom igle v pretisnem omotu.
• Belly, except for a 5 cm (2-inch) area right around your belly button 
• trebuh (razen v predelu 5 cm okrog popka)